BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Citi
US Army
Mallinckrodt
Medtronic
Argus Health
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson
Julphar

Generated: January 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,060,939

« Back to Dashboard

Which drugs does patent 9,060,939 protect, and when does it expire?

Patent 9,060,939 protects LYSTEDA and is included in one NDA.

This patent has eight patent family members in two countries.
Summary for Patent: 9,060,939
Title:Tranexamic acid formulations
Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
Inventor(s): Moore; Keith A. (Loveland, OH), Heasley; Ralph A. (Webster Grove, MO), Greiwe; Jeffrey S. (Ft. Thomas, KY), Facemire; John W. (Douglasville, GA), Modest; Jason D. (Minneapolis, MN)
Assignee: Ferring B.V. (Hoofddorp, NL)
Application Number:13/230,902
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 9,060,939

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ferring Pharms As LYSTEDA tranexamic acid TABLET;ORAL 022430-001 Nov 13, 2009 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,060,939

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,791,160 Tranexamic acid formulations ➤ Subscribe
7,947,739 Tranexamic acid formulations ➤ Subscribe
8,022,106 Tranexamic acid formulations ➤ Subscribe
8,809,394 Tranexamic acid formulations ➤ Subscribe
8,487,005 Tranexamic acid formulations ➤ Subscribe
8,273,795 Tranexamic acid formulations ➤ Subscribe
8,957,113 Tranexamic acid formulations ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,060,939

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2014193878 ➤ Subscribe
Japan 2011168596 ➤ Subscribe
Japan 5205053 ➤ Subscribe
Japan 2008508275 ➤ Subscribe
Japan 5000504 ➤ Subscribe
Japan 2008508276 ➤ Subscribe
World Intellectual Property Organization (WIPO) 2006023000 ➤ Subscribe
World Intellectual Property Organization (WIPO) 2006023001 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
QuintilesIMS
Chubb
Johnson and Johnson
Queensland Health
Colorcon
Mallinckrodt
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot